← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $624B	2,096	-10	-0.5%	$172B
2	2 Pfizer PFE $169B	1,880	-8	-0.4%	$139B
3	3 Merck MRK $372B	1,673	-53	-3%	$103B
4	4 AbbVie ABBV $510B	1,605	-49	-3%	$62B
5	5 Gilead Sciences GILD $197B	1,575	+14	+0.9%	$115B
6	6 Bristol-Myers Squibb BMY $125B	1,454	+6	+0.4%	$72.3B
7	7 Amgen AMGN $238B	1,382	+15	+1%	$84.4B
8	8 Novartis NVS $288B	926	-19	-2%	$21.6B
9	9 GSK GSK $99.2B	707	-14	-2%	$8.54B
10	10 Regeneron Pharmaceuticals REGN $83.1B	563	+22	+4%	$34.1B
11	11 AstraZeneca AZN $261B	371	-5	-1%	$6.54B
12	12 Incyte INCY $23.1B	364	+30	+9%	$19.1B
13	13 Jazz Pharmaceuticals JAZZ $14B	362	-12	-3%	$7.51B
14	14 Opko Health OPK $1.19B	268	+49	+22%	$1.04B
15	15 Myriad Genetics MYGN $415M	235	0	0%	$3.42B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	224	+4	+2%	$5.48B
17	17 DELISTED Assertio ASRT	208	+4	+2%	$1.12B
18	CLVS 18 DELISTED Clovis Oncology, Inc. CLVS	192	+15	+8%	$3.28B
19	19 DELISTED Exact Sciences EXAS	192	-11	-5%	$1.65B
20	20 Halozyme HALO $13.8B	175	+17	+11%	$1.32B
21	21 Precigen PGEN $2.66B	173	0	0%	$3.23B
22	22 Puma Biotechnology PBYI $545M	163	-35	-18%	$2.27B
23	23 DELISTED Chimerix, Inc. CMRX	157	+1	+0.6%	$1.6B
24	24 DELISTED Lumos Pharma, Inc. Common Stock LUMO	152	+7	+5%	$569M
25	25 DELISTED Immunogen Inc IMGN	151	+11	+8%	$748M